There is no fixed dosage regimen for management of diabetes mellitus with glipizide extend - RELEASE Tablets or any other Hypoglycemic agent. Because of the extensive protein binding of glipizide, dialysis is unlikely to be of benefit. Clearance of glipizide FROM plasma may be prolonged in persons with liver disease. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. This should be followed by continuous infusion of more dilute glucose solution at a rate that will maintain blood glucose at a level above 100 mg / dL. If Hypoglycemic coma is diagnosed or suspect, patient should be given rapid intravenous injection of concentrated glucose solution. Severe Hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring IMMEDIATE hospitalization. Close monitoring should continue until the physician is assured that the patient is out of danger. Mild Hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and / or meal patterns. Overdosage of sulfonylureas including glipizide, can produce hypoglycemia. In nonclinical studies, acute oral toxicity of glipizide was extremely low in all species test. There have been no known suicide attempts associated with purposeful overdosing with glipizide extend - RELEASE Tablets. There is no well - documented experience with glipizide extend - RELEASE Tablets overdosage in humans.
0 kommentar(er)
